Cardiac amyloidosis is a progressive stiffening of the heart muscle that leads to heart failure. There are two main types of disease and treatment differs accordingly. Several cardiac biomarkers are useful for disease diagnosis, staging and therapeutic decision making. CLI chatted to Dr Andreea Foghis (Washington University in Saint Louis, MO, USA) to discover more […]
Although great developments have been made in treating lung cancer, it remains the most common cause of cancer deaths, largely because patients present late with advanced disease. Timely and accurate reporting of biomarker analysis is crucial for directing physicians to the most appropriate therapy for the patient. CLI chatted to Dr Brandon Sheffield (molecular pathologist […]
by Dr Gard Myrmel We have known for a while now that the symptoms of acute coronary syndromes can be different for women compared to men. Here, Dr Myrmel discusses how the differences between the sexes also extend to the prognostic value of circulating biomarkers in patients presenting with acute chest pain.
by PD Dr Angelika Hammerer-Lercher Measurement of cardiac-specific troponin I or T forms is part of the diagnostic pathway to rule in or rule out acute coronary syndromes, such as heart attack, as well as for prognostication of future cardiovascular disease. CLI chatted to Dr Angelika Hammerer-Lercher (Chief Physician and Director of Central Medical Laboratories, […]
by Dr Aleksandra Havelka Assays for NT-proBNP form a key part of diagnosing/ruling out, predicting and managing heart failure. CLI chatted to Dr Aleksandra Havelka (Gentian Diagnostics) to find out more about the challenges and limitations of measuring NT-proBNP concentrations, particularly the effects of glycosylation, and what developments are on the horizon to overcome these […]
Novo Nordisk will acquire Cardior Pharmaceuticals for up to €1.025 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved.
by Dr Roopa Rao and Arden Shen The incidence of heart failure (HF) is increasing globally. Biomarkers in HF play a key role in diagnosis and prognostication. Ideal biomarkers should be easily measurable with distinct values in normal physiology, disease state and be a marker of therapeutic intervention. Several biomarkers have emerged that are potentially […]
Bio-Rad Laboratories has expanded compatibility of its newest cardiac control, Cardiac Advance, to now include Beckman-Coulter instruments.
May 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.